Maintenance therapy for HER2-positive advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a maintenance therapy (treatment given to keep cancer from growing) for women with HER2-positive breast cancer that has spread or can't be removed. It may help if you haven't had much treatment yet for your advanced cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- Your breast cancer is HER2-positive (a protein that helps cancer grow) and has spread or can't be removed by surgery.
- You have not had chemotherapy or other targeted therapy for your advanced cancer (up to one hormone therapy is allowed).
- If you had treatment before your cancer came back, it must have been more than 12 months ago.
- You are able to do daily activities (performance status 0 or 1) and have adequate organ function.
- You agree to use birth control and avoid breastfeeding during and for 7 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three targeted drugs (pyrotinib plus trastuzumab and pertuzumab) as maintenance therapy to help keep advanced HER2-positive breast cancer under control after initial successful treatment. The goal is to see if this triple-drug approach works better than the standard two-drug maintenance.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) as maintenance therapy to keep HER2-positive breast cancer that has spread under control. It is for women who have already received some first-line treatment and are stable enough to continue therapy.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
This Phase 2 study tests whether adding trastuzumab (a targeted antibody) given with chemo and extra drugs can better treat certain HER2-positive, locally advanced or inflammatory breast cancers. It may help by improving cancer control in people who have not had prior anti-cancer treatment for their breast cancer.
This trial tests a treatment for early-stage HER2-positive breast cancer that is small and has not spread to lymph nodes. It aims to reduce the chance of cancer returning after surgery.
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.